Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
04 2020
Historique:
received: 31 10 2018
revised: 09 02 2019
accepted: 15 02 2019
pubmed: 27 3 2019
medline: 27 6 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal stem cell disorder. Eculizumab and bone marrow transplantation are disease-modifying treatments for PNH but may not be readily available in resource-constrained settings. Of 52 pediatric patients with PNH, 20 had classical PNH and 32 had PNH/aplastic anemia (PNH/AA). Median time to diagnosis was 30 months in classical PNH patients. Renal failure was present in four patients (20%). Six (30%) achieved complete response, 10 (50%) achieved partial response with androgens in classical PNH. Two underwent allogenic stem cell transplantation. In the PNH/AA group, 16 (50%) were in CR and seven (21%) were in PR with anti-thymocyte globulin ± cyclosporine.

Identifiants

pubmed: 30912620
doi: 10.1002/pbc.27712
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e27712

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.
Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow- up and prognostic factors-French Society of Haematology. Lancet. 1996;348:573-577.
Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med. 1991;325:991-996.
Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330:249-255.
Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703-711.
Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587-3591.
de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099-3106.
Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal hemoglobinuria. Nat Rev Dis Primers. 2017;3:17028.
Borowit MJ, Crag FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010;78(4):211-230.
Endo M, Beatty PG, Vreeke TM, Wittwer CT, Singh SP, Parker CJ. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood. 1996;88:742-750.
Graham ML, Rosse WF, Halperin EC, Miller CR, Ware RE. Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1996;92:707-710.
Flotho C, Strahm B, Kontny U, et al. Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood. Br J Haematol. 2002;118:124-127.
Miller DR, Baehner RL, Diamond LK. Paroxysmal nocturnal hemoglobinuria in childhood and adolescence: clinical and erythrocyte metabolic studies in two cases. Pediatrics. 1967;39:675-688.
Kletzel M, Arnold WC, Berry DH. Paroxysmal nocturnal hemoglobinuria presenting as recurrent hemolytic uremic syndrome. Clin Pediatr. 1987;26:319-320.
Lin HC, Chen RL, Wang PJ. Paroxysmal nocturnal hemoglobinuria presenting as moyamoya syndrome. Brain Dev. 1996;18:157-159.
Rizk S, Ibrahim IY, Mansour IM, Kandil D. Screening for paroxysmal nocturnal hemoglobinuria (PNH) clone in Egyptian children with aplastic anemia. J Trop Pediatr. 2002;48:132-137.
Wyatt HA, Mowat AP, Layton M. Paroxysmal nocturnal haemoglobinuria and Budd-Chiari syndrome. Arch Dis Child. 1995;72:241-242.
Wainwright L, Brodsky RA, Erasmus LK, Poyiadjis S, Naidu G, MacKinnon D. Paroxysmal nocturnal hemoglobinuria arising from Fanconi anemia. J Pediatr Hematol Oncol. 2003;25:167-168.
van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol. 2005;128:571-577.
Naithani R, Mahapatra M, Dutta P, Kumar R, Pati HP, Choudhry VP. Paroxysmal nocturnal hemoglobinuria in childhood and adolescence-a retrospective analysis of 18 cases. Indian J Pediatr. 2008;75:575-578.
Curran KJ, Kernan NA, Prockop SE, et al. Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer. 2012;59:525-529.
Young NS, Maciejewski JP, Sloand E, et al. The relationship of aplastic anemia and PNH. Int J Hematol. 2002;76(Suppl. 2):168-172.
Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897-3902.
Narita A, Muramatsu H, Okuno Y, Sekiya Y. Development of clinical paroxysmal nocturnal hemoglobinuria in children with aplastic anemia. Br J Haematol. 2017;178:954-958.
Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804-2811.
Bourantas K. High-dose recombinant human erythropoietin and low dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta Haematol. 1994;91:62-65.
Marwaha RK, Bansal D, Trehan A, Varma N. Androgens in childhood acquired aplastic anemia in Chandigarh, India. Tropical Doctor. 2004;34:149-152.
Andolin JR, Reinis AL, Akhta R, et al. Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children. Pediatr Blood Cancer. 2018;65(8):e27218.

Auteurs

Rohan Halder (R)

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Priyanka Mishra (P)

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Mukul Aggarwal (M)

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Rishi Dhawan (R)

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Tulika Seth (T)

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Manoranjan Mahapatra (M)

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Renu Saxena (R)

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH